# EDGAR Filing Document

**Accession Number:** 0001551966
**File Stem:** 0001551966-25-000007
**Filing Date:** 2025-11
**Character Count:** 11280
**Document Hash:** 7ff9af98091c45339bd968239ada3e13
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001551966-25-000007.hdr.sgml**: 20251112

**ACCESSION NUMBER**: 0001551966-25-000007

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251107

**FILED AS OF DATE**: 20251112

**DATE AS OF CHANGE**: 20251112

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Hopfner Robert Lorne
- **CENTRAL INDEX KEY:** 0001551966

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42938
- **FILM NUMBER:** 251473085

**MAIL ADDRESS:**
- **STREET 1:** C/O BAY CITY CAPITAL, LLC
- **STREET 2:** 750 BATTERY STREET, SUITE 400
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94111
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Evommune, Inc.
- **CENTRAL INDEX KEY:** 0002044725
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 850742575
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 1841 PAGE MILL RD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304
- **BUSINESS PHONE:** (650) 223-7745

**MAIL ADDRESS:**
- **STREET 1:** 1841 PAGE MILL RD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Hopfner Robert Lorne<br><sub>(Last) (First) (Middle)</sub><br>C/O EVOMMUNE, INC.<br>1841 PAGE MILL ROAD, SUITE 100<br><sub>(Street)</sub><br>PALO ALTO, CA 94304<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-07 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Evommune, Inc. [ EVMN ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-11-07 |  | C |  | 3026 | A | <sup>(1)</sup> | 3026 | I | By Trust<sup>(2)</sup> |
| Common Stock | 2025-11-07 |  | C |  | 1441032 | A | <sup>(1)(3)(4)(5)</sup> | 1441032 | I | By NFLS Delta III Limited<sup>(6)</sup> |
| Common Stock | 2025-11-07 |  | C |  | 1632441 | A | <sup>(1)(3)(4)(5)</sup> | 1632441 | I | By Pivotal bioVenture Partners Fund I, L.P.<sup>(7)</sup> |
| Common Stock | 2025-11-07 |  | C |  | 294502 | A | <sup>(5)</sup> | 294502 | I | By Pivotal bioVenture Partners Fund II, L.P.<sup>(8)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Series Seed Preferred Stock | <sup>(1)</sup> | 2025-11-07 |  | C |  |  | 25790 | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 3026 | <sup>(1)</sup> | 0 | I | By Trust<sup>(2)</sup> |
| Series Seed Preferred Stock | <sup>(1)</sup> | 2025-11-07 |  | C |  |  | 7145647 | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 838886 | <sup>(1)</sup> | 0 | I | By NFLS Delta III Limited<sup>(6)</sup> |
| Series Seed Preferred Stock | <sup>(1)</sup> | 2025-11-07 |  | C |  |  | 3572816 | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 419441 | <sup>(1)</sup> | 0 | I | By Pivotal bioVenture Partners Fund I, L.P.<sup>(7)</sup> |
| Series A Preferred Stock | <sup>(3)</sup> | 2025-11-07 |  | C |  |  | 2582243 | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 324578 | <sup>(3)</sup> | 0 | I | By NFLS Delta III Limited<sup>(6)</sup> |
| Series A Preferred Stock | <sup>(3)</sup> | 2025-11-07 |  | C |  |  | 7230283 | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 908821 | <sup>(3)</sup> | 0 | I | By Pivotal bioVenture Partners Fund I, L.P.<sup>(7)</sup> |
| Series B Preferred Stock | <sup>(4)</sup> | 2025-11-07 |  | C |  |  | 1895260 | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 240756 | <sup>(4)</sup> | 0 | I | By NFLS Delta III Limited<sup>(6)</sup> |
| Series B Preferred Stock | <sup>(4)</sup> | 2025-11-07 |  | C |  |  | 2104740 | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 267367 | <sup>(4)</sup> | 0 | I | By Pivotal bioVenture Partners Fund I, L.P.<sup>(7)</sup> |
| Series C Preferred Stock | <sup>(5)</sup> | 2025-11-07 |  | C |  |  | 313571 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 36812 | <sup>(5)</sup> | 0 | I | By NFLS Delta III Limited<sup>(6)</sup> |
| Series C Preferred Stock | <sup>(5)</sup> | 2025-11-07 |  | C |  |  | 313571 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 36812 | <sup>(5)</sup> | 0 | I | By Pivotal bioVenture Partners Fund I, L.P.<sup>(7)</sup> |
| Series C Preferred Stock | <sup>(5)</sup> | 2025-11-07 |  | C |  |  | 2508575 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 294502 | <sup>(5)</sup> | 0 | I | By Pivotal bioVenture Partners Fund II, L.P.<sup>(8)</sup> |

---

### Footnotes:

(1) Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-8.518 basis and had no expiration date.

(2) The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

(3) Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date.

(4) Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date.

(5) Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.

(6) Securities are directly held by NFLS Delta III Limited ("NFLS Delta"). NFLS Delta is a wholly-owned indirect subsidiaries of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by NFLS Delta are made by the members of Nan Fung Group Holdings Limited's Life Sciences Investment Committee, who are Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

(7) Securities are directly held by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal I"). Pivotal bioVenture Partners Fund I G.P., L.P., the general partner of Pivotal I, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal I are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund I G.P., L.P., who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

(8) Securities are directly held by Pivotal bioVenture Partners Fund II, L.P. ("Pivotal II"). Pivotal bioVenture Partners Fund II G.P. Ltd,, the general partner of Pivotal II, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal II are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund II G.P. Ltd, who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

**Signature:** /s/ Gregory S. Moss, Attorney-in-Fact  
**Date:** 2025-11-12

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**